Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Foxy-5 as neoadjuvant therapy in Wnt-5a low colon cancer
2018-003074-27Phase 2Suspended
- Sponsor
- WntResearch AB
- Start
- Oct 2018
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Foxy-5 in colon adenocarcinoma (2 arms), sponsored by WntResearch AB. Primary endpoint: Incidence of Foxy-5 related AEs and Grade ≥3 AEs. Started Oct 2018; status: suspended.
02
Drugs
Foxy-5
03
Conditions
colon adenocarcinoma
Beyond the preview
Go deeper on 2018-003074-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003074-27.